| Bioactivity | Dolutegravir intermediate-1 is a synthetic intermediate of Dolutegravir extracted from patent WO 2016125192 A2. Dolutegravir is an integrase inhibitor developed for the treatment of human immunodeficiency virus (HIV)-1 infection. | ||||||||||||
| Name | Dolutegravir intermediate-1 | ||||||||||||
| CAS | 1335210-23-5 | ||||||||||||
| Formula | C13H17NO8 | ||||||||||||
| Molar Mass | 315.28 | ||||||||||||
| Appearance | Solid | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. Sivaram Prasad, et al. Process for the preparation of dolutegravir . WO 2016125192 A2. |
Dolutegravir intermediate-1
CAS: 1335210-23-5 F: C13H17NO8 W: 315.28
Dolutegravir intermediate-1 is a synthetic intermediate of Dolutegravir extracted from patent WO 2016125192 A2. Dolutegr
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.